News and Trends 22 Mar 2017 Swedish Oncology Biotech Teams up with World Leading Cancer Center The Swedish biotech Aprea Therapeutics has entered a new collaboration with the Memorial Sloan Kettering Cancer Center to study the effects of its lead APR-246. Based in Stockholm, Aprea therapeutics is focusing on the development of its only drug candidate, APR-246. The molecule targets the key tumor supressor p53 to restore its function. Now, in collaboration […] March 22, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 22 Mar 2017 France’s 2nd Biggest Pharma Enters New Partnership for Immunotherapies With its new Fund for Innovation, Pierre Fabre will collaborate with H-Immune to use its ‘In Vitro Immunization’ (IVI) platform for the development of fully human monoclonal antibodies (mAbs). Pierre Fabre is the 2nd largest private pharmaceutical company in France and has recently made efforts to open up its innovation process. Since the establishment of the Pierre […] March 22, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 22 Mar 2017 Watch a Partner at Spain’s Largest VC talk Investment Strategy At BIO Europe Spring, we met Karen Wagner, a General Partner at Ysios, the VC dominating Spain’s investment scene. She told us what’s on the firm’s radar. Spain’s largest VC has positioned itself in Barcelona, having identified the city’s potential to be the next biotech hub in Europe. It has funded key biotechs in Spain, including Sanifit, which claimed the […] March 22, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 22 Mar 2017 What’s the Gold Standard for Therapeutic Antibodies? Are fully human antibodies the new gold standard in therapeutic innovation? If you want to upgrade, here’s where to find them. If you’re curious about the future of antibody development, look no further than Humira. This monoclonal antibody (mAb) for various inflammatory diseases soared to become the best-selling biological in 2016. Humira is a fully human […] March 22, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2017 A Potential First Treatment for a Rare Genetic Disease clears Phase I Minoryx Therapeutics has successfully completed a Phase I trial for its lead compound MIN-102 targeting X-linked adrenoleukodystrophy (X-ALD). The Spanish biotech Minoryx is specialized on orphan diseases and its lead program is a PPAR-gamma agonist, MIN-102, which is in development for X-ALD. The company now announced the successful results of its Phase I trial with MIN-102 revealing the […] March 21, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 21 Mar 2017 Better than Quantum Computing: The EU Launches a Biocomputer Project The EU Horizon 2020 has launched Bio4Comp, a five-year €6.1M project to build more powerful and safer biocomputers that could outperform quantum computing. The Bio4Comp project has the ambitious goal of building a computer with greater processing speed and lower energy consumption than any of the most advanced computers existing today. Ultimately, this could translate into […] March 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 21 Mar 2017 Rethinking Profits: Can a Socially Conscious Model work in Biotech? As biopharma continues to weather a maelstrom of public scrutiny for its prices and profits, I asked executives about alternative models. Conventional wisdom in biotech is that the non-profit model can’t work in the industry: it takes a decade and billions in cash to develop a drug, with no guaranteed success. No investor would sink […] March 21, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 20 Mar 2017 Immuno-oncology is Overcrowded – Here is Where Startups Can Succeed The unprecedented competition in the field represents a daunting challenge for companies trying to break in. A BIO-Europe Panel discussed remaining niches. BIO Europe’s panel on immuno-oncology was perhaps the most popular of the day, as attendees filled the room to hear the thoughts of John Haurum, CEO of F-star; Christophe Quéva, CSO of iTeos; and […] March 20, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2017 Will BMS Take Over a Danish Biotech in a Massive €400M Deal? Galecto Biotech has presented positive data from a Phase II study with its pulmonary fibrosis candidate, giving BMS the option of take over the biotech. In 2014, Denmark’s Galecto Biotech has signed an option agreement with US-based pharma Bristol-Myers Squibb (BMS) for its lead asset TD139, which is under development for the treatment of pulmonary […] March 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 20 Mar 2017 UPDATE: Swiss Medtech cancels IPO and goes for Record €411M Exit UPDATE (10/04/2017): Symetis has decided to cancel its IPO following its acquisition by Boston Scientific in a €411M deal. The Swiss medtech company Symetis has launched a €55M IPO to accelerate the development of its next-generation heart valve replacement solutions. Symetis develops next-generation heart valve replacements for the treatment of cardiac valve conditions. With its […] March 20, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2017 French Biotech fails Second Phase II Trial for Cardiovascular Disease Cerenis therapeutic’s lead candidate CER-001 has failed Phase II for the treatment of patients with post-acute coronary syndrome (ACS). The French-based Biotech Cerenis is developing therapies for the treatment of cardiovascular and metabolic diseases. The company now presented data on its lead candidate CER-001, which was investigated in a Phase II study for the treatment of patients with post-acute […] March 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 20 Mar 2017 Machines are Helping Healthcare: An Interview with their Biotech Leader BenevolentAI is leading the charge in artificial intelligence. We talked to Jackie Hunter, who is the CEO of the company’s bioscience arm, BenevolentBio. Jackie Hunter has had quite an impressive career! After defending her PhD in psychology, she transitioned to GSK, where she clocked nearly 20 years in various leadership positions — Director while the […] March 20, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email